The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: Incremental prognostic benefit of cardiac 123I-mIBG scintigraphy

[1] Ezekowitz JA(2003)Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials Ann Intern Med 138 445-452

[2] Armstrong PW(2004)Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials J Am Coll Cardiol 44 2166-2172

[3] McAlister FA(2008)ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons J Am Coll Cardiol 51 e1-e62

[4] Nanthakumar K(2007)Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study J Am Coll Cardiol 50 1150-1157

[5] Epstein AE(2008)American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention J Am Coll Cardiol 52 1179-1199

[6] Kay GN(2004)Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator Circulation 110 3760-3765

[7] Plumb VJ(2008)Prognostic importance of defibrillator shocks in patients with heart failure N Engl J Med 359 1009-1017

[8] Lee DS(2005)Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction ≤30% should receive an implantable cardioverter-defibrillator Circulation 111 2537-2549

[9] Epstein AE(1986)Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies Am J Physiol Imaging 1 96-103

[10] DiMarco JP(2009)Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion J Am Coll Cardiol 53 426-435

[1] Ezekowitz JA(2003)Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials Ann Intern Med 138 445-452

[2] Armstrong PW(2004)Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials J Am Coll Cardiol 44 2166-2172

[3] McAlister FA(2008)ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons J Am Coll Cardiol 51 e1-e62

[4] Nanthakumar K(2007)Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study J Am Coll Cardiol 50 1150-1157

[5] Epstein AE(2008)American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention J Am Coll Cardiol 52 1179-1199

[6] Kay GN(2004)Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator Circulation 110 3760-3765

[7] Plumb VJ(2008)Prognostic importance of defibrillator shocks in patients with heart failure N Engl J Med 359 1009-1017

[8] Lee DS(2005)Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction ≤30% should receive an implantable cardioverter-defibrillator Circulation 111 2537-2549

[9] Epstein AE(1986)Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies Am J Physiol Imaging 1 96-103

[10] DiMarco JP(2009)Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion J Am Coll Cardiol 53 426-435